State Street Corp Acquires 1,895,529 Shares of Humacyte, Inc. (NASDAQ:HUMA)

State Street Corp boosted its stake in shares of Humacyte, Inc. (NASDAQ:HUMA - Free Report) by 66.1% in the 3rd quarter, according to the company in its most recent disclosure with the SEC. The firm owned 4,764,155 shares of the company's stock after buying an additional 1,895,529 shares during the quarter. State Street Corp owned approximately 3.99% of Humacyte worth $25,917,000 as of its most recent SEC filing.

Other large investors have also added to or reduced their stakes in the company. nVerses Capital LLC bought a new position in shares of Humacyte during the 2nd quarter valued at approximately $28,000. Concurrent Investment Advisors LLC purchased a new position in Humacyte in the third quarter valued at approximately $75,000. Principal Financial Group Inc. bought a new position in Humacyte during the second quarter valued at $83,000. FORA Capital LLC purchased a new stake in Humacyte in the third quarter worth $96,000. Finally, Profund Advisors LLC bought a new stake in shares of Humacyte in the second quarter valued at $97,000. Hedge funds and other institutional investors own 44.71% of the company's stock.

Humacyte Price Performance

Humacyte stock traded up $0.01 during midday trading on Monday, reaching $4.65. 12,118,879 shares of the stock were exchanged, compared to its average volume of 2,774,191. Humacyte, Inc. has a 52 week low of $2.48 and a 52 week high of $9.97. The company has a debt-to-equity ratio of 0.61, a quick ratio of 1.10 and a current ratio of 1.10. The firm has a market cap of $585.24 million, a PE ratio of -3.47 and a beta of 1.38. The company's fifty day moving average is $4.81 and its 200-day moving average is $5.81.

Analyst Upgrades and Downgrades

HUMA has been the subject of several research reports. Piper Sandler set a $6.00 price target on Humacyte and gave the stock a "neutral" rating in a research note on Friday, October 18th. EF Hutton Acquisition Co. I upgraded shares of Humacyte to a "strong-buy" rating in a research report on Monday, September 9th. D. Boral Capital reissued a "buy" rating and issued a $25.00 price target on shares of Humacyte in a research report on Friday. Cantor Fitzgerald restated an "overweight" rating and set a $13.00 price target on shares of Humacyte in a research note on Friday, September 20th. Finally, TD Cowen reiterated a "buy" rating and issued a $10.00 price objective on shares of Humacyte in a research note on Friday, October 18th. One analyst has rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the company's stock. According to MarketBeat, the stock has a consensus rating of "Buy" and an average price target of $13.71.

Insider Activity

In other Humacyte news, CEO Laura E. Niklason sold 261,369 shares of the firm's stock in a transaction dated Wednesday, November 20th. The stock was sold at an average price of $4.40, for a total value of $1,150,023.60. Following the sale, the chief executive officer now owns 1,730,884 shares of the company's stock, valued at $7,615,889.60. This trade represents a 13.12 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, Director Brady W. Dougan sold 427,459 shares of the business's stock in a transaction dated Tuesday, November 19th. The stock was sold at an average price of $4.34, for a total value of $1,855,172.06. Following the transaction, the director now directly owns 1,992,253 shares of the company's stock, valued at $8,646,378.02. The trade was a 17.67 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 1,500,000 shares of company stock worth $6,606,799 in the last three months. Corporate insiders own 11.20% of the company's stock.

About Humacyte

Humacyte, Inc engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection.